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Abstract
Background: To define the clinical target volume (CTV) for radiotherapy in patients with hepatocellular carcinoma
(HCC).
Methods: A prospective study was conducted to histologically evaluate the presence and the distance of
microscopic extension (ME) for resected HCC on the basis of examination of whole-mount preparations of
carcinoma tissue sections.
Results: A total of 380 whole-mount slides prepared from tumor samples of 76 patients with HCC were examined.
Patients with elevated pretreatment AFP levels exhibited higher risk of ME as compared to those with normal
pretreatment AFP levels (93.9% vs. 69.8%, P < 0.01). ME positivity was 16.7% for Grade 1, 79.1% for Grade 2, and
96.3% for Grade 3 tumors (P < 0.01). The mean distance of ME was 0.0 ± 0.1 mm (range 0-0.2 mm) for Grade 1,
0.9 ± 0.9 mm (range 0-4.5 mm) for Grade 2, and 1.9 ± 1.9 mm (range 0-8.0 mm) for Grade 3 tumors (P < 0.01).
Conclusions: The CTV margins for tumor Grades 1, 2, and 3 HCC, are recommended to be 0.2 mm, 4.5 mm, and
8.0 mm beyond the gross tumor margin, respectively, to account for possible ME of the tumors in all patients.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy and the third leading cause of cancer
mortality worldwide [1]. It is estimated that in 2009,
there will be 22,620 new cases of liver cancer and
18,160 related deaths in America [2]. It is the third
most common cancer and the second leading cause of
cancer-related death in China [3,4]. The mainstay of
therapy is surgical resection with a 5-year survival rate
ranging from 30 to 70% [5,6]. Unfortunately, less than
20% of HCC patients are eligible for surgery; surgery is
ruled out in many patients because of inadequate liver
function reserve, the multifocal nature of the disease,
and the proximity to and/or involvement of vascular or
biliary structures [7,8]. Traditionally, the role of radio-
therapy in the management of HCC has been limited by
the low tolerance of the liver to radiation. However,
recent advances in radiation techniques, such as three-
dimensional conformal radiation therapy (3D-CRT),
intensity-modulated radiation therapy (IMRT), image-
guided radiation therapy (IGRT), proton therapy,
tumor-tracking, and respiratory gating techniques, have
allowed the administration of high radiation doses to
the primary tumor with sparing of the normal liver tis-
sue [9,10]. Thus, the use of radical radiotherapy for
unresectable HCC has increased dramatically in recent
years, and promising results have been achieved [11-13].
In a radiotherapy setting, a tissue volume inclusive of
the subclinical lesions in addition to the gross tumor is
defined as clinical target volume (CTV). Modern ima-
ging techniques enable precise delineation of gross
tumor volume (GTV); however, none of the available
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distance of the microscopic extension (ME) of HCC. It
has not been possible to clearly define the CTV of HCC.
Taking ME into account, a margin of 1.0 to 1.5 cm is
arbitrarily added to the GTV to obtain the CTV [11-13].
It remains to be ascertained whether this margin is ade-
quate to cover ME in patients with HCC. A narrow
margin is associated with the increased risk of local fail-
ure, while a generous margin results in increased radia-
tion damage to normal tissues. Therefore, guidelines for
the extent of ME to be included within the radiation
volume would be very useful in clinical practice. In this
prospective study, we histologically evaluated the ME of
HCC using whole-mount slides that should allow for a
more representative assessment of the ME by increasing
t h ea m o u n to ft i s s u ee x a m i n e dc o m p a r e dt or o u t i n e
small histopathologic slides and defined the CTV as pre-
cisely as possible.
Materials
Case selection
Between June, 2007, and March, 2009, we prospectively
enrolled 76 patients with pathologically diagnosed HCC
who underwent tumor resection at the Cancer Institute
and Hospital, Peking Union Medical College and Chi-
nese Academy of Medical Sciences (Beijing, China). The
pretreatment evaluation for all patients consisted of a
complete history taking, physical examination, serologi-
cal tests to screen for hepatitis B virus (HBV) and hepa-
titis C virus (HCV), a-fetoprotein (AFP) assay,
prothrombin time test (PT), complete blood counts,
serum biochemical tests, abdominal computed tomogra-
phy (CT) with arterial- and portal-venous-phase imaging
or MRI, and chest radiography. The time scale from
imaging studies and laboratory tests to surgery was
within 3 weeks before surgery. The criteria for inclusion
in this study were as follows: (1) resectable hepatic
lesion with clinical stage I and II disease determined
according to the American Joint Committee on Cancer
(AJCC 2002); (2) radical resection with a margin ≥1c m
around the gross tumor; (3) detection of a single lesion
without satellite nodules in the pretreatment CT or dur-
ing the operation; (4) no history of previous treatment.
The protocol was approved by the institutional review
boards, and written informed consent was obtained
from all the patients.
ME measurement
After fixation of the resected specimen in 13% neutral
buffered formalin for ≥12 h, transverse sections were
obtained with an average thickness of 10 mm, which
were completely embedded in paraffin blocks. The par-
affin blocks were cut into 4-μm-thick sections, and
whole mount slides of these tissues were stained with
hematoxylin and eosin (HE) and evaluated using a light
microscope (Olympus BX40; Olympus, Tokyo, Japan).
To avoid interobserver variations, the same pathologist
(Xiaoli Feng) who particularly experienced in the assess-
ment of hepatic lesions assessed all the slides and identi-
fied evidence of ME. ME was considered as positive if
extension was detected microscopically, even if it was
absent on imaging studies. If a tumor had multiple MEs,
the longest distance between the tumor margin of the
ME was recorded. ME was determined by light micro-
scopy at a magnification of ×40 and was confirmed, if
required, by examination at ×100 magnification.
The following features were recorded for each case:
(1) ME status (positive versus negative), defined as posi-
tive if ME was identified; (2) ME distance, defined as
the maximum linear distance from the capsular margin
of the primary gross tumor to the farthest extent of the
ME. We did not account for tissue shrinkage in this
study because of the fixation of the tumor sections.
Statistical analysis
Statistical analysis was performed using SPSS version
11.0 statistical package (SPS SI n c . ,C h i c a g o ,I L ) .T h e
clinical characteristics were analyzed using a chi-square
test or Fisher’s exact test (two-tailed) for categorical
variables and logistic regression analysis for continuous
variables. The Student’su n p a i r e dt test was used to
determine the significance of the difference between the
2 sample means. The association of these characteristics
with ME distance was analyzed using logistic or linear
regression models. Multivariate analyses were performed
using a multiple logistic regression model. A P value
less than or equal to 0.05 was considered statistically
significant.
Results
Patient characteristics
Patient characteristics and ME status are summarized in
Table 1. The median age at the time of operation was
53 years (range, 25-78 years). The median pretreatment
AFP level was 13.1 ng/ml (mean, 1776.9 ng/ml; range,
1~50781 ng/ml). The median tumor size measured
on enhanced CT was 5.0 cm (mean, 5.1 cm; range
1.6-10.2 cm) in the greatest dimension. Only 1 of the
patients had Child-Pugh Class B cirrhosis, while the
others had Child-Pugh Class A cirrhosis.
Factors associated with the presence of ME
In this study, the average number of slides for each
patient investigated histologically was 5 (range 2-
11 slides), and 380 slides of these tumor specimens were
reviewed. Of the 76 patients with HCC, 61 (80.3%)
p a t i e n t sh a dM E ,a n d1 5( 1 9 . 7 % )p a t i e n t sd i dn o th a v e
ME. As shown in Table 1, factors associated with the
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tumor grade. Patients with elevated pretreatment AFP
level (>25 ng/ml) exhibited higher risk of ME compared
with those with normal pretreatment levels (93.9% vs.
69.8%, P < 0.01). ME was more frequently detected in
high-grade tumors than in low-grade tumors. ME posi-
tivity was 16.7% (1/6) for Grade 1, 79.1% (34/43) for
Grade 2, and 96.3% (26/27) for Grade 3 tumors (P <
0.01). The pretreatment hepatitis B surface antigen and
hepatitis C virus antibody statuses; the serum levels of
aspartate aminotransferase, alanine aminotransferase, g-
glutamyltransferase, total bilirubin, and albumin; platelet
count; tumor size; tumor-node-metastasis (TNM) stage;
and prothrombin time did not correlate with the pre-
sence of ME. On multivariate analysis, only tumor grade
remained significantly and independently associated
with ME positivity (P < 0.01).
Factors associated with ME distance
The ME distance for HCC are listed in Table 2. Of the
76 patients, the median ME distance was 1.0 mm
(mean, 1.2 mm; range, 0-8 mm). The majority (72/76,
94.7%) of patients had ME ≤ 3.5 mm, whereas 4 patients
had ME of 4.5 mm (n = 2), 7.0 mm and 8.0 mm, respec-
tively. Only the tumor grade was found to significantly
correlate with the distance of ME (P < 0.01).
Of the 76 patients, 6 (7.9%) patients had tumors of
Grade 1; 43 (56.6%), of Grade 2; and 27 (35.5%), of
Grade 3. Figure 1 shows the relationship between tumor
grade and the mean distance of ME, with higher grade
tumors having a greater distance of ME. When evalu-
ated by tumor grade, the distance (mean ± SD) of ME
was 0.0 ± 0.1 mm (median, 0.0 mm; range 0-0.2 mm)
for Grade 1, 0.9 ± 0.9 mm (median, 0.80 mm; range
0-4.5 mm) for Grade 2, and 1.9 ± 1.9 mm (median,
1.5 mm; range 0-8.0 mm) for Grade 3 tumors (P < 0.01).
Figure 2 presents the cumulative distribution of the
ME in patients with tumors of Grades 2 and 3. A com-
parison between the distributions of these 2 grades indi-
cated that most of the Grade 2 (67.4%) and Grade 3
(66.7%) tumors had ME of 0.1-1.9 mm. Grade 1 tumors
were not included in this analysis owing to the small
number of patients with this tumor type, and 5 out of
6 patients did not have ME.
Discussion
Microscopic extension of the primary tumor plays a
significant role in defining the CTV for radiotherapy.
A quantitative pathologic assessment of subclinical
tumor invasion from primary tumor or metastatic
lymph nodes into adjacent tissues for planning external-
beam radiotherapy has been performed successfully for
Table 1 Patient characteristics and ME status
Patients ME positive
Characteristic No (%) % P value
Age (y) NS
≤60 39 (51.3) 87.2
>60 37 (48.7) 73.0
Sex NS
Male 60 (78.9) 78.3
Female 16 (21.1) 87.5
Status of Hepatitis
HBsAg positive 62 (81.6) 85.5 NS
HCVAb positive 3 (3.9) 33.3
Others 11 (14.5) 63.6
AFP level (ng/ml) <0.01
Normal 43 (56.6) 69.8
Elevated 33 (43.4) 93.9
Tumor size (cm) NS
≤5 41 (53.9) 78.0
>5 35 (46.1) 82.9
TNM stage NS
I 42 (55.3) 83.3
II 34 (44.7) 76.5
Platelets (G/L) NS
<100 11 (14.5) 81.8
≥100 65 (85.5) 80.0
AST level (U/L) NS
≤40 54 (71.1) 85.2
>40 22 (28.9) 68.2
ALT level (U/L) NS
≤40 49 (71.1) 81.6
>40 27 (28.9) 77.8
GGT level (U/L) NS
≤55 43 (56.6) 81.4
>55 33 (43.4) 78.8
Albumin level(g/L) NS
≤35 8 (10.5) 75.0
>35 68 (89.5) 80.9
BIL (μmol/L) NS
≤17.1 59 (77.6) 78.0
>17.1 17 (22.4) 88.2
PT(s) NS
≤13.3 55 (72.4) 83.6
>13.3 21 (27.6) 71.4
Tumor grade <0.01
1 6 (7.9) 16.7
2 43 (56.6) 79.1
3 27 (35.5) 96.3
All patients 76 (100) 80.3 –
Abbreviations: HBsAg = hepatitis B surface antigen; HCV Ab = hepatitis C virus
antibody; AFP = serum a-fetoprotein; AST = serum aspartate aminotransferase
level; ALT = serum alanine aminotransferase level; GGT = serum g-
glutamyltransferase; BIL = serum total bilirubin level; PT = prothrombin time;
NS = not significant.
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tate, and bladder cancers [14-22]. There are few relevant
data available for hepatocellular carcinoma [23]. To our
knowledge, this is the first prospective study to evaluate
the ME of tumors using whole-mount preparations in
patients with hepatocellular carcinoma. The present
study showed that ME occurred more frequently among
patients with an elevated AFP level than those with nor-
mal AFP levels. The tumor grade is significantly asso-
ciated with both the presence and the extent of ME.
Developments in radiation techniques have enabled
the safe delivery of dose-escalated conformal radiation
to a wide spectrum of patients with inoperable HCC.
Several studies have shown an improved response and
survival rates with the administration of a high radiation
dose in these patients [12,24-26]. The University of
Michigan conducted a phase I/II trial of 128 patients
with unresectable intrahepatic malignancies receiving
Table 2 ME distance (mm) by clinical characteristics
Characteristic ME extent (mean ± SD) P value
Age (y) NS
≤60 1.3 ± 1.4
>60 1.0 ± 1.5
Sex NS
Male 1.2 ± 1.5
Female 1.1 ± 0.9
Status of Hepatitis
HBsAg positive 1.3 ± 1.5 NS
HCVAb positive 0.3 ± 0.6
Others 1.0 ± 1.1
AFP level (ng/ml) NS
Normal 1.1 ± 1.5
Elevated 1.3 ± 1.3
Tumor size (cm) NS
≤5 1.2 ± 1.3
>5 1.2 ± 1.5
TNM stage NS
I 1.2 ± 1.4
II 1.2 ± 1.5
Platelets (G/L) NS
<100 1.3 ± 2.0
≥100 1.2 ± 1.3
AST level (U/L) NS
≤40 1.3 ± 1.5
>40 1.0 ± 1.3
ALT level (U/L) NS
≤40 1.2 ± 1.4
>40 1.1 ± 1.5
GGT level (U/L) NS
≤55 1.0 ± 0.9
>55 1.4 ± 1.9
Albumin level(g/L) NS
≤35 1.0 ± 0.8
>35 1.2 ± 1.5
BIL (μmol/L) NS
≤17.1 1.2 ± 1.5
>17.1 1.1 ± 1.1
PT(s) NS
≤13.3 1.3 ± 1.5
>13.3 1.0 ± 1.1
Tumor grade <0.01
1 0.0 ± 0.1
2 0.9 ± 0.9
3 1.9 ± 1.9
All patients 1.2 ± 1.4 –
Abbreviations: As in table 1.
Figure 1 Correlation between tumor grades and the mean
distance of microscopic extension (ME).
Figure 2 Cumulative distribution of microscopic extension (ME)
according to tumor grade. Grade 1 was not included in this
analysis due to the small number of patients with tumors of this
grade, and 5 out of 6 patients did not have ME.
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floxuridine. Patients who received a dose ≥75 Gy had
significantly higher survival rates compared to those
receiving a dose of <75 Gy (23.9 months vs. 14.9
months, P < 0.01) [24,27]. Similarly, Park et al. and
Seong et al. reported the results of a study on 158 HCC
patients classified with Child-Pugh class A or B liver dis-
ease, who were prescribed radiation doses of 25-60 Gy
in daily fractions of 1.8-Gy [25,28]. The total radiation
dose was found to be the only significant factor in pre-
dicting tumor response and survival. Other studies have
also reported that the radiation dose appeared to be a
significant prognostic factor in radiation response of
patients with HCC [11,12,26]. However, the treatment
benefits observed with increased radiation doses come
at a cost because toxicity risks increase proportionally
with the increases in radiation dose and large treatment
volume [25]. Even in 3D-CRT or IMRT, the dose deliv-
ery for the disease is limited by the sensitivity of liver
tissue to ionizing radiation. Therefore, in the case of
h i g h - d o s e3 D - C R To rI M R Tf o rH C Ct r e a t m e n t ,t h e
adequate treatment of the tumor, including the primary
tumor and subclinical lesions and the radiation toler-
ance of the healthy surrounding tissue need to be
balanced well. In other words, it is very important to
estimate the microscopic extension as accurately as pos-
sible. Unfortunately, there was no precise definition of
the optimal CTV margins; therefore, no optimal treat-
ment plan for patients with HCC has been defined. Sev-
eral previous studies have used a margin of 1.0 cm to
1 . 5c mf r o mt h eG T Vt od e t e r m i n et h eC T V ;t h i se s t i -
mation of the margin is largely empirical and mainly left
to the discretion of the physician. In this study, the
majority (94.7%) of patients with HCC had ME ≤ 3.5
mm, and the extent of ME depended on the tumor
grade. Only 4 of 76 patients had ME > 4.0 mm beyond
the GTV. The CTV margins of 0.2, 4.5, and 8.0 mm
beyond the gross tumor would have been adequate to
cover all the ME observed in this study for tumor
Grades 1, 2, and 3, respectively, in all patients with
HCC. Similarly, Wang et al retrospectively reviewed 300
slides from tumor samples of 149 patients with HCC
using routine histopathologic preparations and recom-
mended GTV-to-CTV expansions of 4 mm with 100%
accuracy [23].
The level of serum AFP is associated with both survi-
val and intrahepatic recurrence for HCC [29-32]. Mon-
torsi et al. reported that the level of AFP is an
independent predictor of disease recurrence in patients
with HCC [31]. Imamura et al. revealed that a serum
AFP level ≥32 ng/ml contributed to early intrahepatic
recurrence of HCC after hepatectomy [32]. These find-
ings were supported by the outcome of our study, in
which a high prevalence of ME was noted in patients
with an elevated AFP level. A previous study confirmed
that the extent of microinvasion of HCC was correlated
with high AFP levels [23]. However, elevated AFP levels
were not associated with the distance of the ME in our
study, this finding requires validation with larger patient
numbers. Other studies suggest that serum AFP level
probably reflects the degree of cellular differentiation,
and thus, the extent of the tumor invasion [33-36].
Interestingly, the presence and extent of ME of prostatic
carcinomas have also shown to correlate with increased
PSA levels in patients with early stages of prostate can-
cer [17,18].
High tumor grades are associated with poor outcome
for HCC patients. Shah et al. demonstrated that moder-
ate (hazard ratio [HR], 3.0; 95% confidence interval [CI],
1.4-6.7) and poor (HR, 3.3; 95% CI, 1.3-8.3) tumor dif-
ferentiation is an independent predictor of recurrence
after resection of HCC [37]. Cucchetti et al. analyzed
the prognostic factors of recurrence after resection of
HCC; the results showed that poorly differentiated and
undifferentiated tumors have a higher recurrence rate
(54%) than well-differentiated and moderately differen-
tiated tumors (25%; P = 0.015) [38]. Wayne et al. also
demonstrated that tumor grade is a risk factor for HCC
recurrence after resection [39]. Our data indicated that
tumor grade was significantly associated with both the
presence and extent of ME. Similarly, other studies
revealed a significant correlation between the extent of
extracapsular extension and higher Gleason scores in
prostate cancer patients [17,18,40]. These data may par-
tially explain why tumor recurrence was more frequent
in patients with high-grade tumors than in those with
low-grade tumors.
In this series, no correlation was observed between
tumor size and extent of ME in HCC, which is consis-
tent with the findings of other studies focusing on the
extent of ME in metastatic lymph nodes and primary
lung cancers [15,21]. These correlations of the extent of
ME with the pathological features of the tumor and not
the tumor size signify that ME may be related to the
biological characteristics of the primary tumor. In con-
trast, a correlation between tumor size and the presence
or extent of microinvasion was observed in a previous
study of 149 patients with HCC [23]. Therefore, the cor-
relations of the extent of ME with the tumor grade or
the tumor size are needed to be further validated in the
near future.
This is only a prospective study to evaluate micro-
scopic extension using whole-mount preparations of
HCC; however, our study has some potential limitations.
First, the slides of specimens were only representative
2-dimensional sections of the resected tumor and may
not really illustrate the ME in 3 dimensions. Some ME
measurements may have been slightly underestimated.
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median of 5 slides examined per patient. Third, this
study addressed histologic data, not radiographic. So
even though ME was found beyond the histologically
visible gross disease, this does not necessarily relate to
the CTV and GTV, as used in radiation therapy, which
are radiographically based definitions. Fourth, tissue
shrinkage was not taken into consideration in this study.
In a well-designed analysis of patients with prostate can-
cer, Schned et al. observed only 4.3% linear tissue
s h r i n k a g eb e t w e e nt h em i c r o s c o p i cs l i d ea n dt h ef r e s h
specimen [41]. From a volumetric standpoint, it can be
postulated that tissue shrinkage is lesser in HCC than in
prostate cancer, owing to the presence of smooth mus-
cles in the prostate gland and the absence of myofibro-
blastic cells in the liver parenchyma and neoplasms.
Thus, it can be assumed that tissue shrinkage may be
much smaller, perhaps even negligible.
Conclusions
In summary, our clinicopathologic analysis indicated
that the incidence of ME positively correlated with ele-
vated AFP levels and high grades of tumor and that the
extent of ME appears to be related only to the tumor
grade. Although the optimal CTV of HCC remains
undefined, it is reasonable to recommend CTV margins
extending to ≤8 mm beyond the GTV for all tumor
grades in patients with HCC.
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